Muhammad Delwar Hussain, M.Pharm., Ph.D.
Professor, Pharmaceutical Sciences
Education
- Ph.D. – Pharmaceutical Sciences (Pharmacokinetics), University of Alberta, Edmonton, AB, Canada
- M.Pharm. – Pharmacy, University of Dhaka, Bangladesh
- B.Pharm. – Pharmacy, University of Dhaka, Bangladesh
Bio
Dr. Hussain, Professor of Pharmaceutical Sciences, has been teaching pharmaceutics, pharmacokinetics and pharmacology. Prior to joining UMES, he served as Professor and Interim Chair at the Department of Pharmaceutical and Biomedical Sciences, and Director of Pharmaceutical Research at College of Pharmacy, California Health Sciences University. Dr. Hussain has 25+ years of teaching experience in professional pharmacy and graduate programs.
In addition to his academic career, Dr. Hussain worked in Pharmaceutical Industries. His work at pharmaceutical industries resulted in marketed products such as USFDA approved oncology drug product, Eligard® for treatment of prostate cancer.
Dr. Hussain has a broad research background in nanomedicine, drug delivery, drug development, pharmacokinetics, and cancer therapeutics. He utilizes advanced nanotechnologies, molecular pharmaceutics and in-vivo studies for effective treatment of cancer and other diseases with reduced side effects and better management of patients. He has published extensively in these research areas and trained many scientists, post-doctoral fellows, graduate (PhD and MS), professional (PharmD, MD) and undergraduate students. His research has been funded by Federal, State, and Industrial grants.
Dr. Hussain served as Chair for both Community of Nanotechnology, and Nanotechnology Focus Group, American Association of Pharmaceutical Scientists (AAPS). Currently, he is a steering committee member of the Community of Nanotechnology, AAPS. He also served as chair of Pharmaceutics Section, American Association of Colleges of Pharmacy (AACP) and as Expert Committee member of the United States Pharmacopeia (USP).
Areas of research interests:
- Development of novel nano-careers for targeted drug and gene delivery
- Combination chemo/therapeutics for treatment of resistant cancer
- Cancer metastasis and tumor microenvironment derived exosome
